Barclays
LUMO

Barclays’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Barclays’s Portfolio LUMO Stock Details LUMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-111
Closed -$2K – 7428
2018
Q3 		$2K Buy
+111
New +$3.38K ﹤0.01% 6972
2018
Q2 		– Sell
-789
Closed -$51K – 7357
2018
Q1 		$51K Sell
789
-978
-55% -$69.3K ﹤0.01% 5894
2017
Q4 		$129K Buy
1,767
+723
+69% +$59.8K ﹤0.01% 5039
2017
Q3 		$96K Buy
1,044
+555
+113% +$42.6K ﹤0.01% 4971
2017
Q2 		$32K Buy
489
+389
+389% +$48.2K ﹤0.01% 5583
2017
Q1 		$22K Sell
100
-1,467
-94% -$210K ﹤0.01% 5771
2016
Q4 		$145K Hold
1,567
– – ﹤0.01% 4473
2016
Q3 		$212K Sell
1,567
-1,411
-47% -$140K ﹤0.01% 3925
2016
Q2 		$302K Buy
2,978
+1,411
+90% +$175K ﹤0.01% 3621
2016
Q1 		$254K Hold
1,567
– – ﹤0.01% 3673
2015
Q4 		$508K Buy
+1,567
New +$510K ﹤0.01% 3205
2015
Q2 		– Sell
-4,444
Closed -$2.16M – 7252
2015
Q1 		$2.16M Buy
+4,444
New +$1.72M ﹤0.01% 2245
2014
Q2 		– Sell
-2,922
Closed -$736K – 7843
2014
Q1 		$736K Sell
2,922
-27,078
-90% -$8.28M ﹤0.01% 3563
2013
Q4 		$5.94M Hold
30,000
– – 0.01% 1675
2013
Q3 		$4.86M Buy
+30,000
New +$4.83M 0.01% 1706

Other funds holding LUMO

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
IFG
Investors Financial Group Plymouth, Minnesota $215M AUM 19.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Barclays's LUMO Position: Q1 2020 in Review

Barclays sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q1 2020, closing a stake of 1 share.

Barclays first reported a position in LUMO in Q2 2013 and held it in 27 quarters. The position peaked at $8.31M in Q1 2015. 46 funds tracked by Wall St. Rank hold LUMO as of Q1 2020.

  • Barclays reported no remaining Lumos Pharma, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Barclays sold 1 Lumos Pharma, Inc. Common Stock share in Q1 2020.
  • Barclays first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2013 and held it in 27 quarters.
  • Barclays's Lumos Pharma, Inc. Common Stock position peaked at $8.31M in Q1 2015.
  • 46 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q1 2020.

Based on Barclays's 13F filing for Q1 2020, filed 13 May 2020.